BOK Financial Private Wealth Inc. Trims Position in Thermo Fisher Scientific Inc. $TMO

BOK Financial Private Wealth Inc. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,320 shares of the medical research company’s stock after selling 496 shares during the period. BOK Financial Private Wealth Inc.’s holdings in Thermo Fisher Scientific were worth $1,753,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mondrian Investment Partners LTD grew its holdings in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after acquiring an additional 127,357 shares during the period. TIAA Trust National Association grew its stake in Thermo Fisher Scientific by 10.5% in the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock worth $50,256,000 after purchasing an additional 11,817 shares during the period. Caledonia Investments PLC raised its holdings in Thermo Fisher Scientific by 11.5% in the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after purchasing an additional 11,500 shares in the last quarter. Heritage Investors Management Corp boosted its holdings in shares of Thermo Fisher Scientific by 9.6% during the 2nd quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock valued at $22,944,000 after buying an additional 4,971 shares in the last quarter. Finally, Foresight Group Ltd Liability Partnership grew its position in shares of Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after buying an additional 56,747 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TMO has been the topic of several research reports. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Citigroup boosted their target price on Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Finally, Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $574.15, for a total transaction of $229,660.00. Following the completion of the sale, the executive vice president directly owned 21,152 shares in the company, valued at $12,144,420.80. The trade was a 1.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,420 shares of company stock valued at $19,980,884 in the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 1.2%

Thermo Fisher Scientific stock opened at $572.72 on Monday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The business’s fifty day moving average is $518.58 and its 200 day moving average is $462.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock has a market capitalization of $215.18 billion, a PE ratio of 33.09, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the business earned $5.28 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.